Loading
companiesCompany
Sino Biopharmaceutical (Chia Tai Tianqing)
Sino Biopharm, through Chia Tai Tianqing, sells anlotinib, one of China's biggest cancer drugs, and acquired LaNova Medicines to add bispecific antibodies and ADCs.
Also called: Sino Biopharm中国生物制药Chia Tai TianqingCTTQChia Tai Tianqing PharmaceuticalNanjing Shunxin Pharmaceutical
· 1 more · Fewer names
Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical
Overview
Anlotinib (Focus V) approved 2018 across lung cancer, sarcoma and thyroid cancer; the PD-L1 antibody benmelstobart (TQB2450) approved 2024 for small cell lung cancer with anlotinib; a large hepatitis and oncology generics franchise. In 2025 it agreed to acquire LaNova Medicines, whose PD-1 x VEGF bispecific LM-299 had been licensed to Merck & Co. in 2024, for up to about $951 million, an example of Chinese pharma buying Chinese biotech.
Headquarters
Hong Kong / Nanjing, CN
Scorecard
All companies#17of 1244 companies, score 110
- approved products +12
- phase 3 +24
- phase 1/2 +7
- targets +28
- modalities +8
- regions +1
- registry trials +30
2 approved, 8 in phase 3, 7 earlier, 14 targets, 583 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2025-07 | LaNova Medicines to Sino Biopharmaceutical (Chia Tai Tianqing) LaNova Medicines (remaining equity), developer of LM-299 (PD-1 x VEGF, licensed to Merck & Co.) and ADCs | Acquisition | not disclosed | up to about $951m | source |
Type
Large pharma · 1177.HK
Stage
Public
Website
ApprovedSmall-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, KIT)
Anlotinib · Focus V
Anlotinib is one of the most used cancer pills in China, first approved for lung cancer after other treatments have failed and then for several rarer tumours.
Phase 2Small-molecule inhibitor
TQB3702 is a small-molecule inhibitor from Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in registered phase 2 trials for non-Hodgkin lymphoma.
Phase 2Small-molecule inhibitor
TQB3909 is a small-molecule inhibitor from Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in registered phase 2 trials for metastatic cancer.
Phase 2Bispecific antibody
TQB2868 is a bispecific antibody from Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., in registered phase 2 trials for pancreatic ductal adenocarcinoma.
ApprovedAnti-PD-L1 monoclonal antibody
Benmelstobart is Chia Tai Tianqing's PD-L1 antibody, approved in China in 2024 for extensive-stage small-cell lung cancer in combination with anlotinib and chemotherapy.
Phase 3small molecule (structure undisclosed or not yet in PubChem)
AL2846 is an experimental small-molecule drug from Chia Tai Tianqing Pharmaceutical in phase 3 trials for thyroid cancer, aimed at MET and RET.
Phase 3monoclonal antibody
LM-108 is an experimental monoclonal antibody from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 3 trials for pancreatic ductal adenocarcinoma and gastric & gastro-oesophageal junction cancer, with its target not yet stated publicly.
Phase 3ADC
LM-302 is an experimental antibody-drug conjugate from LaNova Medicines Zhejiang in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2.
Phase 3small molecule (structure undisclosed or not yet in PubChem)
TQ-B3234 is an experimental small-molecule drug from Chia Tai Tianqing Pharmaceutical in phase 3 trials for rare cancers of childhood, with its target not yet stated publicly.
Phase 3ADC
TQB2102 is an experimental antibody-drug conjugate from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, HER2-positive breast cancer and biliary tract cancer, aimed at HER2.
Phase 3monoclonal antibody
TQB2450 is an experimental monoclonal antibody from Chia Tai Tianqing Pharmaceutical in phase 3 trials for renal cell carcinoma and non-small-cell lung cancer, aimed at PD-L1 and PD-1.
Phase 2bispecific antibody
TQB2825 is an experimental bispecific antibody from Chia Tai Tianqing Pharmaceutical in phase 2 trials for diffuse large B-cell lymphoma, aimed at CD20 and CD3.
Phase 2bispecific antibody
TQB2922 is an experimental bispecific antibody from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 2 trials for colorectal cancer, aimed at EGFR and MET.
Phase 2bispecific antibody
TQB2930 is an experimental bispecific antibody from Chia Tai Tianqing Pharmaceutical in phase 2 trials for HR-positive / HER2-negative breast cancer, aimed at HER2 and EGFR.
Phase 3small molecule (structure undisclosed or not yet in PubChem)
TQB3454 is an experimental small-molecule drug from Chia Tai Tianqing Pharmaceutical in phase 3 trials for biliary tract cancer, aimed at IDH1 / IDH2.
Phase 3small molecule
TQB3616 is an experimental small-molecule drug from Chia Tai Tianqing Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, aimed at CDK4/6.
Phase 2ADC
TQB6411 is an experimental antibody-drug conjugate from Chia Tai Tianqing Pharmaceutical in phase 2 trials for non-small-cell lung cancer and oesophageal cancer, aimed at EGFR and MET.
Similar pages
- TreatmentGarsorasib
Shares D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standar and the tag china.
- PersonYing Cheng
Shares Anlotinib and the tag china.
- CompanyHansoh Pharmaceutical
Shares Merck & Co. (MSD) and the tag china.
- TreatmentPenpulimab
Shares Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C, Clinical Studies for the Treatment of Advanced Solid Tumors, Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence., SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer.
fronts
drugs
Phase 3small molecule (structure undisclosed or not yet in PubChem)
ApprovedSmall-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, KIT)
Anlotinib · Focus V
ApprovedAnti-PD-L1 monoclonal antibody
Phase 3monoclonal antibody
Phase 3ADC
Phase 3small molecule (structure undisclosed or not yet in PubChem)
Phase 3ADC
Phase 3monoclonal antibody
Phase 2bispecific antibody
Phase 2Bispecific antibody
Phase 2bispecific antibody
Phase 2bispecific antibody
Phase 3small molecule (structure undisclosed or not yet in PubChem)
Phase 3small molecule
Phase 2Small-molecule inhibitor
Phase 2Small-molecule inhibitor
Phase 2ADC
companies
trials
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast CancerA Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer PatientsA Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung CancerA Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary CarcinomaA Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With OxalA Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell LymphomaA Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally AdvanA Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene AbnormalityA Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast CancerA Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid MalignanciesA Clinical Trial on the Efficacy and Safety of TQB6411 for InjectionA Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLCA Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid CarcinomaA Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal CanA Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung CancerA Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerA Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract CancerA Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal CancerA Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast CancerALTER 0303Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.Clinical Studies for the Treatment of Advanced Solid TumorsClinical Studies of TQB2930 Injection for the Treatment of Advanced Solid TumorsClinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort CClinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic NeoplasmsClinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast CancerClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction AdenocarcinomaClinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal CancerClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast CancerClinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell LymphomaClinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell LymphomaClinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part SarcomaD-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior StandarEfficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver MetastasisEvaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform NeurofibromasEvaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast CancerGarsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLCPenpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ASacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal CancerThe Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast CancerTo Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast CancerTQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal CancerTQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerTrametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC